News
With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...
Zacks Investment Research on MSN4h
Exelixis Gains 15.6% YTD: How Should You Play the Stock?
Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...
With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback